Rhythm Pharmaceuticals (RYTM) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.9 million.
- Rhythm Pharmaceuticals' Income towards Parent Company fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2572.22%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
- As of Q3 2025, Rhythm Pharmaceuticals' Income towards Parent Company stood at -$52.9 million, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' Income towards Parent Company peaked at $43.8 million during Q1 2021, and registered a low of -$141.4 million during Q1 2024.
- Its 5-year average for Income towards Parent Company is -$44.9 million, with a median of -$44.2 million in 2023.
- Per our database at Business Quant, Rhythm Pharmaceuticals' Income towards Parent Company soared by 22805.88% in 2021 and then plummeted by 22007.09% in 2022.
- Rhythm Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$50.9 million in 2021, then grew by 16.44% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 3.98% to -$43.3 million in 2024, then fell by 22.2% to -$52.9 million in 2025.
- Its Income towards Parent Company was -$52.9 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$49.5 million in Q1 2025.